Stocks · News reference
This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mixed price-target changes.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BioMarin Stops Voxzogo Development for Noonan Syndrome
BioMarin Pharmaceutical announced it is discontinuing development of Voxzogo for Noonan syndrome due to study feasibility and treatment landscape concerns, though not due to safety or efficacy issues. Despite this setback, Voxzogo generated $472 million in first-half 2026 sales (up 9% YoY) and is on track to achieve blockbuster status with expected 2026 sales of $1.00-$1.05 billion. The drug faces increasing competition from Ascendis Pharma's Yuviwel and BridgeBio's infigratinib, though BioMarin secured a royalty-bearing settlement with Ascendis.
Why Is Ascendis Pharma Stock Trading Lower on Tuesday?
Ascendis Pharma shares dip as it reclaims TransCon technology rights from Novo Nordisk and initiates a $400 million share repurchase program.
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
Shares of U.S.-traded companies with Brazil exposure are trading higher after the first round of Presidential election balloting showed right-wing candidate Flavio Bolsonaro with a lead over Lula, the current left-wing President. The results may indicate a possible pro-business final election outcome ahead of the October 25 run-off vote, wherein the winning candidate must achieve a majority above 50%.
HSBC Downgrades Banco Santander to Hold, Lowers Price Target to $6.2
HSBC analyst Carlos Gomez-Lopez downgrades Banco Santander (NYSE:BSBR) from Buy to Hold and lowers the price target from $7.2 to $6.2.